• NicOx SA, of Sophia Antipolis, France, described the blood pressure results from the 301 Phase III study for naproxcinod in detail in the September 2009 issue of the American Journal of Cardiology. Naproxcinod is the first-in-class cyclooxygenase-inhibiting nitric oxide donating anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis. Submission of a new drug application to the FDA is planned later this month, and the submission to European regulators is planned in the fourth quarter.

• Mesoblast Ltd., of Melbourne, Australia, said that it completed enrollment of the second group of 20 patients randomized to receive an increased dose of Revascor, its allogeneic adult stem cell product for congestive heart failure. The placebo-controlled trial is being run by Mesoblast's U.S.-based associate company Angioblast Systems Inc. As a result of the enrollment completion, under the terms of a Series B investment from Mesoblast, Mesoblast's equity holding in Angioblast has now converted into 38.4 percent common shares.